Yong Ben, MD, MBA
Dr. Yong (Ben) Ben, MD, MBA, is currently Chief Medical Officer at BioAtla, a San Diego-based biotech company with focuses on oncology with an innovative platform, conditionally active biologics(CAB) as well as Chief Operating Officer and Chief Medical Officer at Himalaya Therapeutics focusing on oncology drug development of BioAtla’s pipeline in China. Dr. Ben is an accomplished and experienced biotechnology drug developer inoncology, joins the BioAtla in May 2017 from AstraZeneca, where he was most recently Global Clinical Lead, Immuno-Oncology. His clinical leadership in pharmaceutical and biotechnology companies led to several oncology drug approvals including, for AstraZeneca, the most recent approval of a PD-L1 antibody, durvalumab (Imfinzi), for the treatment of urothelial cancer, ixazomib (Ninlaro) in multiple myeloma for Millennium/Takeda, axitinib (Inlyta) in renal cancer for Pfizer, and oncolytic virus H101 in head and neck cancer for Shanghai Sunwaybio.
Ben spent over 20 years in industry and academia mainly focusing on oncology. During his 13 years of increasing responsibility in biotechnology and pharmaceutical companies, he has led wide-spectrum clinical development efforts from phase 1 to phase 3 clinical trials, from strategy planning to study execution and BLA/NDA submissions. Prior to his career at AstraZeneca, he was Medical Director, Oncology Clinical Research at Millennium Pharmaceuticals where, in addition to leading the pivotal global phase 3 study for ixazomib in refractory/relapsed multiple myeloma, he was clinical lead in the orteronel and alisertib programs. Prior to that, he was Lead Clinician/Global Medical Monitor, Clinical Development for the Pfizer Oncology Business Unit and earlier was Project Manager, Asia Research & Development for Pfizer Global Research & Development. Ben began his career in industry with Shanghai Sunway Biotech Co., a leader in the field of oncolytic viruses. Ben started his career as a surgical oncologist at Peking Union Medical College Hospital and completed a postdoctoral fellowship at California Pacific Medical Center Research Institute. Ben received his medical degree from Norman Bethune Medical University and his MBA from the University of California, San Diego.
Steve Chin, MD
Steve Chin, MD (University of Arizona School of Medicine), Residency (Wayne State University School of Medicine), Hem/Onc fellowship (Wayne State University School of Medicine), the US Medical Lead for Gastrointestinal and H&N Oncology at Eli Lilly and Company. Selected honor and leadership roles: the lead investigator in GI research group, member of the phase I team and the lead clinician for the Cancer Cellular Therapy “Cabinet” at MUSC Center for Cellular Therapy. Director of Neuro Psycho-Oncology at Hollings Cancer center. Area of focus: Gastrointestinal and H&N Oncology.